Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. (Q52931077)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Hanf G

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Brachmann I

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Seybold J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Kunkel G

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Suttorp N

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Noga O

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

1141-1144

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16918520%20AND%20SRC:MED&resulttype=core&format=json

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

Omalizumab inhibits allergen challenge-induced nasal response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

Immunoglobulin E and its regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

The pharmacological basis of anti-IgE therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X

Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01180.X